Minerva Neurosciences, Inc (NERV) News
Filter NERV News Items
NERV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NERV News From Around the Web
Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Minerva Neurosciences: Q3 Earnings SnapshotBURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported profit of $22.5 million in its third quarter. |
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesBURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024. Roluperidone NDA Update As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Appli |
Minerva Neurosciences: Q2 Earnings SnapshotBURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Tuesday reported a loss of $8.2 million in its second quarter. |
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business UpdatesBURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the second quarter of 2024 ending June 30, 2024. Roluperidone NDA Update During the first quarter of this year, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Let |
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesBURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024. Roluperidone NDA Update On February 27, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its N |
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaBURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. In the CRL, the FDA cited the follow |
Minerva schizophrenia drug rejected by FDAThe agency’s complete response letter knocks back Minerva’s attempt to secure approval of the drug over agency reviewers’ objections. |
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesBURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023. Corporate Update On May 8 2023, the U.S. Food and Drug Administration (FDA) confirmed acceptance for filing of Minerva’s New Drug Application (NDA) for roluperidone f |